HD-OPM Archive
Topics › LDL, ApoB & lipid panel

mRNA therapy REP-0003 aims to reverse plaque in homozygous familial hypercholesterolemia

Louis Nervegna · Jul 10, 2026 · ♥ 8 reactions · 0 comments · original Facebook post
LDL, ApoB & lipid panelPlaque, CAC & CT angiographyPCSK9, ezetimibe & newer drugs
AI summary & key facts

Louis shares a note that Repair Biotechnologies' investigational mRNA therapy REP-0003 received FDA eligibility under the Rare Disease Evidence Principles Pathway for homozygous familial hypercholesterolemia. It aims to remove intracellular cholesterol rather than lower LDL.

This is an exciting new approach to plaque reversal.

Quoted:

Plaque Reversal Takes Aim

Repair Biotechnologies received FDA eligibility under the Rare Disease Evidence Principles Pathway for its investigational mRNA therapy, REP-0003, targeting homozygous familial hypercholesterolemia. Rather than simply lowering LDL cholesterol, the therapy aims to remove intracellular cholesterol that drives plaque formation, opening the door to the possibility of reversing cardiovascular damage rather than just slowing it.

Full Episode on YouTube, Spotify and Apple Podcast. Link in the comment.

#repairbiotechnologiesHD #mrnaHD #reverseHD #rep0003HD #fhHD

← newer: Vitamin D is not a panacea: big trials missed primary endpoiolder: GLP-1 drugs improved testosterone and sperm quality, probabl →